Document:

Exhibit 10.1

            

          

     

    

     

    

    
      [Execution]

      AMENDMENT NO. 2 TO ABL CREDIT AGREEMENT AND AMENDMENT NO. 1 TO GUARANTY AND SECURITY AGREEMENT

      AMENDMENT NO. 2 TO ABL CREDIT AGREEMENT AND AMENDMENT NO. 1 TO GUARANTY AND SECURITY AGREEMENT, dated as of March 8,
        2021 (this “Amendment No. 2”), is by and among Wells Fargo Bank, National Association, a national banking association, as administrative agent for each member of the Lender Group and the Bank Product Providers (in such capacity, together with its
        successors and assigns in such capacity, “Agent”), Wells Fargo Bank, National Association, a national banking association, in its capacity as sole lead arranger (in such capacity, together with its successors and assigns in such capacity, the “Lead
        Arranger”), Wells Fargo Bank, National Association, a national banking association as sole book runner (in such capacity, together with their successors and assigns in such capacity, the “Book Runner”), Wells Fargo Bank, National Association, a
        national banking association, as collateral agent (in such capacity, together with its successors and assigns in such capacity, “Collateral Agent”), Cross Country Healthcare, Inc., a Delaware corporation (“Parent”), Cejka Search, Inc., a Delaware
        corporation (“Cejka”), Cross Country Staffing, Inc., a Delaware corporation (“Cross Country Staffing”), Assignment America, LLC., a Delaware limited liability company (“Assignment America”), Travel Staff, LLC, a Delaware limited liability company
        (“Travel Staff”), Medical Doctor Associates, LLC, a Delaware limited liability company (“Medical Doctor”), OWS, LLC, a Delaware limited liability company (“OWS”), New Mediscan II, LLC, a California limited liability company (“New Mediscan” and
        together with Parent, Cejka, Cross Country Staffing, Assignment America, Travel Staff, Medical Doctor, OWS and those additional persons that hereafter become parties thereto as Borrowers in accordance with the terms thereof, each, a “Borrower” and
        individually and collectively, jointly and severally, the “Borrowers”), MDA Holdings, Inc., a Delaware corporation (“MDA Holdings”), Credent Verification and Licensing Services, LLC, a Delaware limited liability company (“Credent Verification” and
        together with MDA Holdings and those additional persons that hereafter become parties thereto as Guarantors in accordance with the terms thereof, each, a “Guarantor” and individually and collectively, jointly and severally, the “Guarantors”).

      W I T N E S S E T H:

      WHEREAS, Agent, Lenders, Borrowers and Guarantors have entered into senior secured asset-based revolving credit
        facility pursuant to which Lenders (or Agent on behalf of Lenders) have made and may make loans and advances and provide other financial accommodations to Borrowers as set forth in the ABL Credit Agreement, dated as of October 25, 2019, by and
        among Agent, Lenders, Borrowers and Guarantors, as amended by Amendment No. 1 to ABL Credit Agreement, dated as of June 30, 2020, by and among Agent, Lenders, Borrowers and Guarantors (as the same is amended hereby and may from time to time
        hereafter be further amended, modified, supplemented, extended, renewed, restated or replaced, the “Credit Agreement”);

      WHEREAS, in connection to the Credit Agreement, Agent, Borrowers and Guarantors have entered into the Guaranty and
        Security Agreement, dated as of October 25, 2019, by and among Agent, Borrowers and Guarantors (as the same is amended hereby and may from time to time hereafter be further amended, modified, supplemented, extended, renewed, restated or replaced,
        the “Security Agreement”);

      WHEREAS, Borrowers and Guarantors have requested that Agent and Lenders agree to certain amendments to the Credit
        Agreement and Security Agreement and Agent and Lenders are willing to agree to such amendments subject to the terms and conditions contained herein;

      
        
          

      

      
      WHEREAS, Agent, Lenders, Borrowers and Guarantors intend to evidence such amendments pursuant to the terms hereof;

      NOW, THEREFORE, in consideration of the foregoing and the mutual agreements and covenants contained herein, and
        other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows:

      1. Amendments to Credit Agreement.

      1.1. Additional Definitions.  The Credit Agreement is hereby amended to include, in
          addition and not in limitation, the following definitions:

      “Affected Financial Institution” means (a) any EEA Financial Institution or (b) any UK Financial Institution.

      “Amendment No. 2” means Amendment No. 2 to ABL Credit Agreement, dated as of March 8, 2021, by and among Agent,
        Lenders, Borrowers and Guarantors, as the same now exists or may hereafter be amended, amended and restated, modified, supplemented, extended, renewed, restated or replaced.

      “Amendment No. 2 Effective Date” means the first date upon which each of the conditions set forth in Section 7 of
        the Amendment No. 2 have been satisfied (or waived in writing).

      “Amendment No. 2 Fee Letter” means the fee letter, dated as of the Amendment No. 2 Effective Date, by and among
        Borrowers, Agent and Lenders.

      “BHC Act Affiliate” of a Person means an “affiliate” (as such term is defined under, and interpreted in accordance
        with, 12 U.S.C. 1841(k)) of such Person.

      “Covered Entity” means any of the following: (a) a “covered entity” as that term is defined in, and interpreted in
        accordance with, 12 C.F.R. § 252.82(b); (b) a “covered bank” as that term is defined in, and interpreted in accordance with, 12 C.F.R. § 47.3(b); or (c) a “covered FSI” as that term is defined in, and interpreted in accordance with, 12 C.F.R. §
        382.2(b).

      “Covered Party” has the meaning assigned thereto in Section 17.15.

      “Default Right” has the meaning assigned to that term in, and shall be interpreted in accordance with, 12 C.F.R. §§
        252.81, 47.2 or 382.1, as applicable.

      “QFC” has the meaning assigned to the term “qualified financial contract” in, and shall be interpreted in accordance
        with, 12 U.S.C. § 5390(c)(8)(D).

      “QFC Credit Support” has the meaning assigned thereto in Section 17.15.

      “Resolution Authority” means an EEA Resolution Authority or, with respect to any UK Financial Institution, a UK
        Resolution Authority.

      “Supported QFC” has the meaning assigned thereto in Section 17.15.

      “UK Financial Institution” means any BRRD Undertaking (as such term is defined under the PRA Rulebook (as amended
        from time to time) promulgated by the United Kingdom Prudential Regulation Authority) or any person falling within IFPRU 11.6 of the FCA Handbook (as amended from time to time) promulgated by the United Kingdom Financial Conduct Authority, which
        includes certain credit institutions and investment firms, and certain affiliates of such credit institutions or investment firms.

      
        2

        
          

      

      “UK Resolution Authority” means the Bank of England or any other public administrative authority having
        responsibility for the resolution of any UK Financial Institution.

      “U.S. Special Resolution Regimes” has the meaning assigned thereto in Section 17.15.

      1.2. Amendments to Definitions—Bail-In Provisions.

      (a) The definition of the term “Bail-In Action” set forth in Section 1.1 of the Credit Agreement is hereby deleted in its entirety and replaced with the following:

      “Bail-In Action” means the exercise of any Write-Down and Conversion Powers by the applicable
        Resolution Authority in respect of any liability of an Affected Financial Institution.

      (b) The definition of the term “Bail-In Legislation” set forth in Section 1.1 of the Credit Agreement is hereby deleted in its entirety and replaced with the following:

      “Bail-In Legislation” means (a) with respect to any EEA Member Country implementing Article 55 of
        Directive 2014/59/EU of the European Parliament and of the Council of the European Union, the implementing law, regulation, rule or requirement for such EEA Member Country from time to time which is described in the EU Bail-In Legislation Schedule
        and (b) with respect to the United Kingdom, Part 1 of the United Kingdom Banking Act 2009 (as amended from time to time) and any other law, regulation or rule applicable in the United Kingdom relating to the resolution of unsound or failing banks,
        investment firms or other financial institutions or their affiliates (other than through liquidation, administration or other insolvency proceedings).

      (c) The definition of the term “Write-Down and Conversion Powers” set forth in Section 1.1 of the Credit Agreement is hereby deleted in its entirety and replaced with the
          following:

      “Write-Down and Conversion Powers” means, (a) with respect to any EEA Resolution Authority, the
        write-down and conversion powers of such EEA Resolution Authority from time to time under the Bail-In Legislation for the applicable EEA Member Country, which write-down and conversion powers are described in the EU Bail-In Legislation Schedule,
        and (b) with respect to the United Kingdom, any powers of the applicable Resolution Authority under the Bail-In Legislation to cancel, reduce, modify or change the form of a liability of any UK Financial Institution or any contract or instrument
        under which that liability arises, to convert all or part of that liability into shares, securities or obligations of that person or any other person, to provide that any such contract or instrument is to have effect as if a right had been
        exercised under it or to suspend any obligation in respect of that liability or any of the powers under that Bail-In Legislation that are related to or ancillary to any of those powers.

      1.3. Amendment to Definition—Borrowing Base.  The definition of the term “Borrowing Base”
          in the Credit Agreement is hereby deleted in its entirety and replaced with the following:

            “Borrowing Base” means, as of any date of determination, the result of:

      
        3

        
          

      

      
        
                   (a)  the
            sum of:

        

      

      
         

        

        
          (i)    eighty-five percent (85%) of Eligible
              Accounts (other than Eligible Unbilled Accounts) that are unpaid up to ninety (90) days from the original invoice date; plus

          (ii)   the lesser of (A) $20,000,000 and (B)
              eighty-five percent (85%) of Eligible Accounts (other than Eligible Unbilled Accounts) that are unpaid ninety-one (91) days or more from the original invoice date up to one hundred fifty (150) days from the original invoice date; plus

          (iii)  the lesser of (A) $7,500,000 and (B)
              eighty-five percent (85%) of Eligible Accounts (other than Eligible Unbilled Accounts) that are unpaid one hundred fifty-one (151) days or more from the original invoice date up to one hundred eighty (180) days from the original invoice date;
              plus

          (iv)  the lesser of (A) $62,500,000 and (B)
              eighty-five percent (85%) of Eligible Unbilled Accounts that are unpaid up to sixty (60) days from the date of the rendition of the services that are the basis for such Account, provided, that, in no event shall the Eligible Unbilled Accounts
              unpaid more than thirty (30) days from the date of the rendition of the applicable services up to sixty (60) days from the date of the rendition of services included in this calculation exceed $6,250,000, plus

          (v)   the Supplemental Availability, minus

        

      

      
        
                  (b)  the aggregate amount of Reserves established by Collateral Agent from time to time under Section
            2.1(c) of this Agreement.

        

         

        

      

      1.4. Amendment to Definition—Maximum Credit.  The definition of the term “Maximum Credit”
          in the Credit Agreement is hereby deleted in its entirety and replaced with the following:

      “Maximum Credit” means $150,000,000, increased by the amount of any Increase made in accordance
        with Section 2.14 of this Agreement.

      1.5. Amendment to Definition—Supplemental Receivable Availability.  The definition of the
          term “Supplemental Receivable Availability” in the Credit Agreement is hereby deleted in its entirety and replaced with the following:

      “Supplemental Receivable Availability” means the lesser of: (a) sum of (i) five percent (5.0%) of
        the amount of Eligible Accounts (other than Eligible Unbilled Accounts) outstanding up to one hundred eighty (180) days from invoice date, plus (ii) five percent (5.0%) of Eligible Unbilled Accounts up to sixty (60) days from date of service, and
        (b) $9,000,000; provided, that, the Supplemental Receivable
        Availability shall be zero on and after the date that is the last day of the eighth (8th) calendar quarter after the Closing Date (not including the calendar quarter in which the Closing Date occurs).

      1.6. Amendment to Schedule 5.2—Borrowing Base Reporting.  The first row of Schedule 5.2
          to the Credit Agreement is hereby deleted in its entirety and replaced with the following:

      	
              Weekly if Excess Availability falls below the greater of (A) ten percent (10.0%) of the Loan Cap or (B) $12,000,000, for any
                five (5) consecutive Business Days, then, at the request of Administrative Agent and until such date as Excess Availability is greater than or equal to the greater of (A) ten percent (10.0%) of the Loan Cap or (B) $12,000,000 for the
                immediately preceding thirty (30) consecutive days,

               

            	
              (a) a detailed aging, by total, of Borrowers’ accounts receivable and accounts payable, together with a reconciliation and
                supporting documentation for any reconciling items noted.

               

            

      

      

      
        4

        
          

      

      1.7. Notices.  The notice information for any Loan Party set forth in Section 11 of the
          Credit Agreement is hereby deleted in its entirety and replaced with the following:

      

        	
                 
                  If to any Loan Party:

                

              	
                Cross Country Healthcare, Inc.

              
	
                 

              	
                6551 Park of Commerce Blvd, N.W.

              
	
                 

              	
                Boca Raton, FL 33487

              
	
                 

              	
                Attention: William J. Burns

              
	
                 

              	
                Facsimile: (855) 322-1199

              
	
                 

              	
                Email: wburns@crosscountry.com

              
	 	 
	
                
                  with copies to:

                

              	
                Cross Country Healthcare, Inc.

              
	
                 

              	
                6551 Park of Commerce Blvd, N.W.

              
	
                 

              	
                Boca Raton, FL 33487

              
	
                 

              	
                Attention: Susan E. Ball

              
	

              	
                Facsimile: (800) 565-9774

              
	
                
                  with copies to:

                

              	
                Email: sball@crosscountry.com

              
	

              	

              
	

              	
                Morgan Lewis & Bockius LLP

              
	
                 

              	
                101 Park Avenue

              
	
                 

              	
                New York, NY 10148

              
	
                 

              	
                Attention: Patricia F. Brennan

              
	
                 

              	
                Email: patricia.brennan@morganlewis.com

              

      

      

      1.8. Acknowledgement and Consent to Bail-In of Affected Financial Institutions.  Section
          17.14 of the Credit Agreement is hereby deleted in its entirety and replaced with the following:

      17.14  Acknowledgement
            and Consent to Bail-In of Affected Financial Institutions. Notwithstanding anything to the contrary in any Loan Document or in any other agreement, arrangement or understanding among any such parties, each party hereto acknowledges
        that any liability of any Affected Financial Institution arising under any Loan Document, to the extent such liability is unsecured, may be subject to the write-down and conversion powers of the applicable Resolution Authority and agrees and
        consents to, and acknowledges and agrees to be bound by:

      (a)  the application of any Write-Down and Conversion Powers by the applicable Resolution
        Authority to any such liabilities arising hereunder which may be payable to it by any party hereto that is an Affected Financial Institution; and

      (b)  the effects of any Bail-in Action on any such liability, including, if applicable:

      (i)  a reduction in full or in part or cancellation of any such liability;

      
        5

        
          

      

      (ii)  a conversion of all, or a portion of, such liability into shares or other instruments of
        ownership in such Affected Financial Institution, its parent undertaking, or a bridge institution that may be issued to it or otherwise conferred on it, and that such shares or other instruments of ownership will be accepted by it in lieu of any
        rights with respect to any such liability under this Agreement or any other Loan Document; or

      (iii)  the variation of the terms of such liability in connection with the exercise of the
        write-down and conversion powers of the applicable Resolution Authority.

      1.9. Acknowledgement Regarding any Supported QFCs.  Section 17 of the Credit Agreement is
          hereby amended to add a new Section 17.15 as follows:

      17.15  Acknowledgement
            Regarding Any Supported QFCs.  To the extent that the Loan Documents provide support, through a guarantee or otherwise, for Hedge Agreements or any other agreement or instrument that is a QFC (such support, “QFC Credit Support” and
        each such QFC a “Supported QFC”), the parties acknowledge and agree as follows with respect to the resolution power of the Federal Deposit Insurance Corporation under the Federal Deposit Insurance Act and Title II of the Dodd-Frank Wall Street
        Reform and Consumer Protection Act (together with the regulations promulgated thereunder, the “U.S. Special Resolution Regimes”) in respect of such Supported QFC and QFC Credit Support (with the provisions below applicable notwithstanding that the
        Loan Documents and any Supported QFC may in fact be stated to be governed by the laws of the State of New York and/or of the United States or any other state of the United States): In the event a Covered Entity that is party to a Supported QFC
        (each, a “Covered Party”) becomes subject to a proceeding under a U.S. Special Resolution Regime, the transfer of such Supported QFC and the benefit of such QFC Credit Support (and any interest and obligation in or under such Supported QFC and such
        QFC Credit Support, and any rights in property securing such Supported QFC or such QFC Credit Support) from such Covered Party will be effective to the same extent as the transfer would be effective under the U.S. Special Resolution Regime if the
        Supported QFC and such QFC Credit Support (and any such interest, obligation and rights in property) were governed by the laws of the United States or a state of the United States.  In the event a Covered Party or a BHC Act Affiliate of a Covered
        Party becomes subject to a proceeding under a U.S. Special Resolution Regime, Default Rights under the Loan Documents that might otherwise apply to such Supported QFC or any QFC Credit Support that may be exercised against such Covered Party are
        permitted to be exercised to no greater extent than such Default Rights could be exercised under the U.S. Special Resolution Regime if the Supported QFC and the Loan Documents were governed by the laws of the United States or a state of the United
        States.  Without limitation of the foregoing, it is understood and agreed that rights and remedies of the parties with respect to a Defaulting Lender shall in no event affect the rights of any Covered Party with respect to a Supported QFC or any
        QFC Credit Support.

      2. Amendments to Security Agreement.

      2.1. Amendment to Definition—Cash Dominion Event. The definition of the term “Cash
          Dominion Event” in the Security Agreement is hereby deleted in its entirety and replaced with the following:

      “Cash Dominion Event” means either (i) Excess Availability is less than the greater of (A) ten
        percent (10.0%) of the Loan Cap or (B) $12,000,000, for at least five (5) consecutive Business Days or (ii) an Event of Default exists or has occurred and is continuing.

      
        6

        
          

      

      2.2. Amendment to Definition—Cash Dominion Period. The definition of the term “Cash
          Dominion Period” in the Security Agreement is hereby deleted in its entirety and replaced with the following:

      “Cash Dominion Period” means the period commencing after the occurrence of a Cash Dominion Event
        and continuing until the date when (i) for a Cash Dominion Event triggered by clause (i) of the definition thereof, Excess Availability is equal to or greater than the greater of (A) ten percent (10.0%) of the Loan Cap and (B) $12,000,000 for
        thirty (30) consecutive days and (ii) for a Cash Dominion Event triggered by clause (ii) of the definition thereof, the Event of Default giving rise to such Cash Dominion Event is cured or waived or otherwise no longer exists.

      3. Interpretation.  For purposes of this Amendment No. 2, all terms used herein which
          are not otherwise defined herein, including but not limited to, those terms used in the recitals hereto, shall have the respective meanings assigned thereto in the Credit Agreement and Security Agreement, as applicable.

      4. Amendment to Schedule C-1 to Credit Agreement.  Schedule C-1 of the Credit Agreement
          is hereby deleted in its entirety and replaced with Amended Schedule C-1 to Amendment No. 2.

      5. Fees.  In consideration of the amendments set forth herein, Borrowers shall, on the
          Amendment No. 2 Effective Date, pay to each Lender the fees provided for in the Amendment No. 2 Fee Letter.  Such fees shall be fully earned and payable as of the Amendment No. 2 Effective Date. Agent may, at its option, charge such fees to the
          Loan Account on the Amendment No. 2 Effective Date.

      6. Representations, Warranties and Covenants.  Each Loan Party, jointly and severally,
          represents and warrants with and to Agent and Lenders as follows, which representations and warranties shall survive the execution and delivery hereof:

      6.1. This Amendment No. 2 has been duly executed and delivered by each Loan Party that is party hereto.  This Amendment No. 2 constitutes a legal, valid and binding obligation of
          each Loan Party, enforceable against such Loan Party that is party hereto in accordance with its terms, except as enforcement may be limited by equitable principles or by bankruptcy, insolvency, reorganization, moratorium, or similar laws
          relating to or limiting creditors' rights generally.

      6.2. The representations and warranties of each Loan Party or its Subsidiaries contained in the Credit Agreement, the Security Agreement or any of the other Loan Documents shall be
          true and correct in all material respects (except that such materiality qualifier shall not be applicable to any representations and warranties that already are qualified or modified by materiality or Material Adverse Effect (or words of similar
          import) in the text thereof) on and as of the date hereof, as though made on and as of such date (except to the extent that such representations and warranties relate solely to an earlier date, in which case such representations and warranties
          shall be true and correct in all material respects (except that such materiality qualifier shall not be applicable to any representations and warranties that already are qualified or modified by materiality or Material Adverse Effect (or words of
          similar import in the text thereof) as of such earlier date).

      6.3. No Default or Event of Default exists or has occurred and is continuing as of the date of, and after giving effect to, this Amendment No. 2.

      7. Conditions Precedent.  This Amendment No. 2 shall be effective upon the satisfaction of each of the following conditions precedent:

      
        7

        
          

      

      7.1. Agent shall have received each of the following:

      (a) this Amendment No. 2, duly authorized, executed and delivered by the Required Lenders and Loan Parties;

      (b) the Second Amended and Restated Revolving Note, duly authorized, executed and delivered by Borrowers in favor of PNC Bank, National Association;

      (c) the Amendment No. 2 Fee Letter, duly authorized, executed and delivered by Borrowers;

      (d) the secretary’s certificates of directors’ resolutions and other materials and opinion letter of counsel to Loan Parties in each case with respect to this Amendment No. 2;

      7.2. Wells Fargo Bank, National Association and PNC Bank, National Association shall have received payment of the fees provided for in the Amendment No. 2 Fee Letter; and

      7.3. As of the date of this Amendment No. 2, and after giving effect thereto, no Default or Event of Default shall exist or have occurred and be continuing.

      8. Effect of Amendment No. 2.  Except as expressly set forth herein and in prior
          amendments, no other amendments, changes or modifications to the Loan Documents are intended or implied, and in all other respects the Loan Documents are hereby specifically ratified, restated and confirmed by all parties hereto as of the
          effective date hereof and the Loan Parties shall not be entitled to any other or further amendment by virtue of the provisions of this Amendment No. 2 or with respect to the subject matter of this Amendment No. 2.  To the extent of conflict
          between the terms of this Amendment No. 2 and the other Loan Documents, the terms of this Amendment No. 2 shall control.  The Credit Agreement, the Security Agreement and this Amendment No. 2 shall be read and construed as one agreement.  This
          Amendment No. 2 is a Loan Document.  The Credit Agreement remains in full force and effect, and nothing contained in this Amendment No. 2 will constitute a waiver of any right, power or remedy under the Credit Agreement, the Security Agreement or
          any other Loan Document.

      9. Governing Law.  The validity, interpretation and enforcement of this Amendment No. 2
          and any dispute arising out of the relationship between the parties hereto whether in contract, tort, equity or otherwise, shall be governed by the internal laws of the State of New York but excluding any principles of conflicts of law or other
          rule of law that would cause the application of the law of any jurisdiction other than the laws of the State of New York.

      10. Jury Trial Waiver.    LOAN PARTIES, AGENT AND LENDERS EACH HEREBY WAIVES ANY RIGHT
          TO TRIAL BY JURY OF ANY CLAIM, DEMAND, ACTION OR CAUSE OF ACTION ARISING UNDER THIS AMENDMENT NO. 2 OR IN ANY WAY CONNECTED WITH OR RELATED OR INCIDENTAL TO THE DEALINGS OF THE PARTIES HERETO IN RESPECT OF THIS AMENDMENT NO. 2 OR THE TRANSACTIONS
          RELATED HERETO OR THERETO IN EACH CASE WHETHER NOW EXISTING OR HEREAFTER ARISING, AND WHETHER IN CONTRACT, TORT, EQUITY OR OTHERWISE.  LOAN PARTIES, AGENT AND LENDERS EACH HEREBY AGREES AND CONSENTS THAT ANY SUCH CLAIM, DEMAND, ACTION OR CAUSE OF
          ACTION SHALL BE DECIDED BY COURT TRIAL WITHOUT A JURY AND THAT EACH LOAN PARTY, AGENT OR LENDER MAY FILE AN ORIGINAL COUNTERPART OF A COPY OF THIS AMENDMENT NO. 2 WITH ANY COURT AS WRITTEN EVIDENCE OF THE CONSENT OF THE PARTIES HERETO TO THE
          WAIVER OF THEIR RIGHT TO TRIAL BY JURY.

      
        8

        
          

      

      11. Binding Effect.  This Amendment No. 2 shall be binding upon and inure to the benefit
          of each of the parties hereto and their respective successors and assigns.

      12. Waiver, Modification, Etc.  No provision or term of this Amendment No. 2 may be
          modified, altered, waived, discharged or terminated orally, but only by an instrument in writing executed by the party against whom such modification, alteration, waiver, discharge or termination is sought to be enforced.

      13. Further Assurances.  The Loan Parties shall execute and deliver such additional
          documents and take such additional action as may be reasonably requested by Agent to effectuate the provisions and purposes of this Amendment No. 2.

      14. Entire Agreement.  This Amendment No. 2, the Credit Agreement and the other Loan
          Documents represent the entire agreement and understanding concerning the subject matter hereof among the parties hereto, and supersedes all other prior agreements, understandings, negotiations and discussions, representations, warranties,
          commitments, proposals, offers and contracts concerning the subject matter hereof, whether oral or written.

      15. Headings.  The headings listed herein are for convenience only and do not constitute
          matters to be construed in interpreting this Amendment No. 2.

      16. Counterparts.  This Amendment No. 2, any documents executed in connection herewith
          and any notices delivered under this Amendment No. 2, may be executed by means of (i) an electronic signature that complies with the federal Electronic Signatures in Global and National Commerce Act, state enactments of the Uniform Electronic
          Transactions Act, or any other relevant and applicable electronic signatures law; (ii) an original manual signature; or (iii) a faxed, scanned, or photocopied manual signature.  Each electronic signature or faxed, scanned, or photocopied manual
          signature shall for all purposes have the same validity, legal effect, and admissibility in evidence as an original manual signature. Agent reserves the right, in its sole discretion, to accept, deny, or condition acceptance of any electronic
          signature on this Amendment No. 2 or on any notice delivered to Agent under this Amendment No. 2.  This Amendment No. 2 and any notices delivered under this Amendment No. 2 may be executed in any number of counterparts, each of which shall be
          deemed to be an original, but such counterparts shall, together, constitute only one instrument.  Delivery of an executed counterpart of a signature page of this Amendment No. 2 and any notices as set forth herein will be as effective as delivery
          of a manually executed counterpart of this Amendment No. 2 or notice.

      [remainder of page intentionally left blank]

      
        9

        
          

      

      IN WITNESS WHEREOF, the parties hereto have caused this Amendment No. 2 to be duly executed and delivered as of
        the day and year first above written.

      BORROWERS: 

      	 	
              CROSS COUNTRY HEALTHCARE, INC.

               

              By: /s/ W. Larry Cash

                Name: W. Larry Cash

                Title: Director

            

      

      

      

      

      	 	
              CEJKA SEARCH, INC.

                

              By: /s/ W. Larry Cash

                Name: W. Larry Cash

                Title: Director

               

            
	 	
               

              CROSS COUNTRY STAFFING, INC.

               

              By: /s/ W. Larry Cash

                Name: W. Larry Cash

                Title: Director

               

            

      

      

       

      

      	 	
              ASSIGNMENT AMERICA, LLC.

               

              By: /s/ W. Larry Cash

                Name: W. Larry Cash

                Title: Director

               

            
	 	
               

              TRAVEL STAFF, LLC

               

              By: /s/ W. Larry Cash

                Name: W. Larry Cash

                Title: Director

               

            
	 	
               

              OWS, LLC

               

              By: /s/ W. Larry Cash

                Name: W. Larry Cash

                Title: Director

               

            

      

      

      

      

      

      

      
        [Signature Page to Amendment No. 2 to ABL Credit Agreement (Cross Country)]

        

        

      

      
        
          

      

       

      

      	 	
              NEW MEDISCAN II, LLC

                

              By: /s/ W. Larry Cash

                Name: W. Larry Cash

                Title: Director

               

               

               

              MEDICAL DOCTOR ASSOCIATES, LLC

                

              By: /s/ W. Larry Cash

                Name: W. Larry Cash

                Title: Director

               

            

      

      

      	
              GUARANTORS:

            	
              MDA HOLDINGS, INC.

               

              By: /s/ W. Larry Cash

                Name: W. Larry Cash

                Title: Director

            
	 	
               

               

              CREDENT VERIFICATION AND LICENSING SERVICES, LLC

               

              By: /s/ W. Larry Cash

                Name: W. Larry Cash

                Title: Director

            

      

      

      
        [Signature Page to Amendment No. 2 to ABL Credit Agreement (Cross Country)]

        
          
            

        

      

      
        	
                 

              	
                 
                  WELLS FARGO BANK, NATIONAL 

                  ASSOCIATION,

                  

                  a national banking association, as Administrative Agent, 

                  Collateral Agent and as a Lender

                   

                  

                  By:       /s/ Rina Shinoda

                  Name:  Rina Shinoda

                    Its Authorized Signatory

                

              

      

      
        [Signature Page to Amendment No. 2 to ABL Credit Agreement (Cross Country)]

        
          
            

        

      

      

      

      
        	
                 

              	
                 
                  PNC BANK, NATIONAL ASSOCIATION, as a 

                  Lender

                  

                  

                  By:        /s/ William Molyneaux

                  Name:   William Molyneaux

                                Its Authorized Signatory

                

              

      

      
        [Signature Page to Amendment No. 2 to ABL Credit Agreement (Cross Country)]

        
          
            

        

      

      

      

      Amended Schedule C-1

      

      

      

      

      Schedule C-1

        to

        ABL Credit Agreement

      

      

      Commitments

      

      

      

      

      

      

      	
              Lender

            	
              Commitments

            
	
              Wells Fargo Bank, National Association

            	
              $85,000,000

            
	
              PNC Bank, National Association

            	
              $65,000,000

            

      

      

      

      

      

      

      

      

      
        [Amended Schedule C-1]EX-10.1

 Exhibit 10.1 

CONFIDENTIAL SEPARATION AGREEMENT AND GENERAL RELEASE 

This Confidential Separation Agreement and General Release (“Agreement”), dated as of March 4, 2021 (the “Agreement
Date”), is made by and between Harmony Biosciences, LLC, a Delaware limited liability company (the “Company”), and Susan L. Drexler (“Employee”) to ensure the protection of the Company and its business and to fully settle
and resolve any and all issues and disputes arising out of Employee’s employment with and separation from the Company. 

WHEREAS, Employee is an employee of the Company; 

WHEREAS, the Company and Employee have agreed that Employee’s employment with the Company shall be terminated without Cause (as
defined in the Harmony Biosciences Holdings, Inc. Amended and Restated Equity Incentive Plan (the “Company Plan”)), with a planned final day of employment of March 31, 2021, although the Company retains the right to accelerate the
actual final day of employment in its sole discretion (the “Separation Date”); and 
 WHEREAS, in connection with
Employee’s departure from the Company, Employee and the Company desire to enter into this Agreement. 
 NOW, THEREFORE, in
consideration of the promises and the mutual covenants and agreements set forth below and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged by Employee, the Company and Employee agree as follows:

 1. Separation. Employee’s employment with the Company shall terminate on the Separation Date. Between March 4, 2021 and
the Separation Date, Employee shall perform transition services reasonably requested by the Company (“Transition Services”) but shall not be physically present at the Company’s offices unless specifically requested by the Company.
Other than as set forth in Section 2 below, Employee shall not be entitled to receive any salary, severance, bonuses (including, but not limited to, any annual or other bonuses for 2021), benefits of employment, amounts, payments or other
compensation from the Company following the Separation Date; provided, however that Employee shall be paid (a) Employee’s regular base salary through the Separation Date and (b) for the accrued, but unused, vacation days that Employee
has as of the Separation Date, in each case subject to deductions for all applicable taxes and other withholding, with such amounts to be payable in accordance with the Company’s regular payroll practices on the first payroll date after the
Separation Date. 
 Each of the Company and Employee shall use their reasonable best efforts to minimize, to the extent reasonably possible,
the disruption to the business, operations and prospects of the Company relating to, or resulting from, the cessation of Employee’s employment with the Company. Employee (i) agrees to return to the Company all computer, telephonic and
other materials and equipment supplied or otherwise provided or made available to Employee by the Company (including, but not limited to, cell phones, blackberries, printers and tablets) (collectively, “Company Property”) on the Separation
Date and (ii) acknowledges that the Company may, in its sole discretion, either (A) withhold payment of any and all amounts payable to Employee under this Section 1 and/or Section 2 below until Employee so returns all such
Company Property to the Company or (B) deduct from such amounts payable to Employee under this Section 1 and/or Section 2 below the current fair market value (as determined by the Company, in its sole discretion) of any Company
Property not so returned to the Company by Employee on or prior to the Separation Date. 

 On or before the Separation Date, Employee shall also provide the Company with any and all
usernames, passwords, and other information or data that Employee possesses that is needed for the Company to access any systems related to it, including but not limited to online portals, Company computer or software systems, and government access
sites (collectively “Company Access Information”). This Section shall apply to any Company Access Information not provided to the Company on or before the Separation Date. 

2. Consideration of the Company. In consideration for the releases and covenants by Employee in this Agreement, provided that
(a) Employee signs and delivers this Agreement to the Company and does not revoke this Agreement in accordance with Section 14 below, (b) Employee performs the Transition Services, (c) Employee returns the Company Property to the
Company in accordance with Section 1 above, and (d) Employee signs and delivers the Second General Release attached hereto as Exhibit A on the Separation Date, then the Company will: (i) continue to pay Employee’s final monthly
base salary for a period of nine (9) months, less required taxes and withholdings; (ii) if Employee was enrolled in the Company’s group health, dental and vision insurance coverage as of the Separation Date and Employee timely elects
to continue such coverage under COBRA, the Company shall pay the “employer portion” of the premiums for such continuation coverage for nine (9) months following the Separation Date, but in no event beyond the date that Employee
qualifies for health insurance coverage through a new employer, provided that Employee timely pays the “employee portion” of the premiums for such continuation coverage; (iii) at the Company’s expense, provide Employee with six
(6) months of outplacement assistance, using a third party chosen by the Company, in connection with Employee’s employment search; (iv) pay the remaining balance for Employee to complete Employee’s ongoing executive coaching
program; and (v) extend Employee’s period to exercise Employee’s vested Option as described in Section 3 below. 

Employee expressly acknowledges and agrees that (A) none of the payments set forth in this Section 2 shall qualify under the
Company’s 401(k) Plan, (B) except as expressly set forth in Section 1 above and this Section 2, Employee shall not be entitled to receive, and hereby waives and releases any and all claims with respect to, any other salary,
severance, bonuses, benefits of employment, amounts, payments or other compensation whatsoever from the Company (including, but not limited to, any claims under or with respect to the Company’s 401(k) Plan) or its subsidiaries or affiliates.

 3. Equity. Employee’s Stock Option Agreement with a Date of Grant of October 28, 2019 (“Option Agreement”)
remains in full force and effect. Twenty percent (20%) of Employee’s Option has vested as of the Separation Date. If Employee satisfies the conditions set forth in Section 2 above, then the period for Employee to exercise the vested Option
shall be extended from ninety (90) to one hundred and eighty (180) days following the Separation Date. 

  
 2 

 4. Employee Release of Rights and Agreement Not to Sue. Employee (defined for the
purpose of this Section 4 as Employee and Employee’s agents, representatives, attorneys, assigns, heirs, executors, and administrators) fully and unconditionally releases the Company, its parents (including, without limitation, Harmony
Biosciences Holdings, Inc.), subsidiaries, affiliates, indirect affiliates (including, without limitation, Paragon Management Company, Paragon Biosciences, LLC) and any of its or their respective direct or indirect, past or present, directors,
officers, managers, employees, agents, insurers, attorneys, administrators, officials, members, shareholders, divisions, predecessors, successors, employee benefit plans, and the sponsors, fiduciaries, or administrators of the Company’s
employee benefit plans (collectively, the “Released Parties”) from, and agrees not to bring any action, proceeding or suit against any of the Released Parties regarding, any and all liability, claims, demands, actions, causes of action,
suits, grievances, debts, sums of money, agreements, promises, damages, back and front pay, costs, expenses, attorneys’ fees, and remedies of any type, known or unknown, from the beginning of time through the date on which Employee executes
this Agreement, arising or that may have arisen out of or in connection with Employee’s employment with or termination of employment from the Company, including, but not limited to, claims, actions or liability under or with respect to:
(a) Title VII of the Civil Rights Act of 1964, the Civil Rights Act of 1991, the Civil Rights Act of 1866, the Age Discrimination in Employment Act, the Americans with Disabilities Act, the Fair Labor Standards Act, the Family and Medical Leave
Act, the Workers’ Adjustment and Retraining Notification, the Employee Retirement Income Security Act of 1974, in each case as such act may be amended; (b) any other federal, state or local statute, act, ordinance, or regulation regarding
employment, termination of employment, discrimination in employment or harassment, (c) federal, state or local common law relating to employment contracts, wrongful discharge, defamation, discrimination in employment or harassment or any other
matter, and (d) any other federal, state or local statute, act, ordinance, regulation, constitution or common law or any violation or alleged violation thereof. Excluded from this release and waiver are any claims that cannot be waived by law.
Nothing in this Agreement shall be construed to prohibit Employee from initiating or maintaining a charge of discrimination with the Equal Employment Opportunity Commission or any of its state or local governmental agency counterparts, or from
otherwise fully cooperating with and/or participating in any investigation by any such agency. Employee is, however, waiving Employee’s right to any monetary recovery should any such agency pursue any claims on Employee’s behalf. Nothing
in the foregoing, or otherwise in this Agreement, shall be a release of (i) any claims to enforce this Agreement; (ii) any claims arising out of events occurring after the execution of this Agreement; (iii) any vested rights or
interests in Company retirement, benefit or equity plans; (iv) any claims for unemployment compensation; (v) any claims for indemnity in the event Employee is named or threatened to be named in any lawsuit or other proceeding arising out
of the services she provided to the Company; or (vi) any claims that, as a matter of law, cannot be released by private agreement. 

  
 3 

 Employee agrees and affirms that Employee has been paid, in full, for all hours worked
for the Company. 
 5. Preservation of Employee Non-Competition and Confidentiality
Agreement. Employee acknowledges and agrees that (a) the provisions of the Employee Non-Competition and Confidentiality Agreement, signed on November 1, 2019 (the “Confidentiality
Agreement”) remain in full force and effect after the Separation Date, (b) Employee agrees to continue to be bound by all such provisions thereafter, and (c) the amounts payable by Company under this Agreement shall be subject to
immediate forfeiture by Employee to the Company if Employee materially breaches any such provision or this Agreement. Without limiting the generality of the foregoing, with respect to the Confidentiality Agreement, Employee agrees to refrain from
using, or disclosing to anyone, any Confidential Information (as defined in the Confidentiality Agreement) and to, no later than the Separation Date, (i) return to the Company all written or printed documents, all tapes, discs and other
electronic media and all other tangible property containing any such Confidential Information and (ii) destroy all other electronic media (whether e-mails, text messages or otherwise) relating to the
Company or any such Confidential Information, in each case (i.e., (i) or (ii)) without retaining any electronic, physical or other form of photocopy or duplicate thereof. Notwithstanding any other provision of this Agreement, Employee may always
communicate directly with a regulatory authority about a possible violation of an applicable law or rule. Without prior authorization from the Company’s Legal department, however, the Company does not authorize Employee to disclose to
regulators a communication that is covered by the Company’s attorney-client privilege. 
 6. No Disparagement or Encouragement of
Claims. Except as required by lawful subpoena or other legal obligation, and except for statements made in connection with any action to enforce this Agreement, Employee agrees not to make any oral or written statement that disparages or places
the Company (including, but not limited to, any of its direct or indirect, past or present, directors, officers, managers, employees, other Released Parties, products or services) in a false or negative light, or to encourage or assist any person or
entity who may or who has filed a lawsuit, claim or complaint against the Released Parties. If Employee receives any subpoena or becomes subject to any legal obligation that implicates this Section 6, Employee will provide prompt written notice
of that fact to the Company’s General Counsel at Harmony Biosciences, LLC, 630 W. Germantown Pike, Suite 215, Plymouth Meeting, PA 19462, and enclose a copy of the subpoena and any other documents describing the legal obligation. The Company,
defined for purposes of this Section 6 as its current officers, shall not make any oral or written statement that disparages or places Employee in a false or negative light. Employee agrees to direct any person seeking an employment
verification or reference to the Company’s Human Resources department, which will provide a neutral reference by confirming only dates of service and positions held, and will state that it is Company policy to provide only such information.
 
 7. Cooperation of Employee. During the twelve (12) month period following the Separation Date, Employee agrees to
cooperate reasonably with the Company and the other Released Parties, for no additional compensation whatsoever (other than reasonable expense reimbursement as provided for in the last sentence of this Section 7), in connection with any
investigation, litigation or potential investigation or litigation or other such legal matters, including, but not limited to, meeting with and fully answering the questions of the Company, any other Released Party or their respective
representatives or agents, and testifying and preparing to testify at any deposition or trial. The Company agrees to reimburse Employee for any reasonable out of pocket expenses, including, but not limited to, attorneys’ fees, travel expenses,
meals and lodging expenses, incurred as a result of such cooperation. 

  
 4 

 8. Non-Admission/Inadmissibility. This
Agreement does not constitute an admission by the Company or any other Released Party that any action that the Company or any of the other Released Parties took with respect to Employee was wrongful, unlawful or in violation of any federal, state or
local statute, act, ordinance, regulation, constitution or common law, or susceptible of inflicting any damages or injury on Employee, and the Company and the other Released Parties specifically deny any such wrongdoing or violation. This Agreement
is entered into solely to resolve fully all matters related to or arising out of Employee’s employment with and termination from the Company, and its existence, execution and implementation may not be used as evidence, and shall not be
admissible in a subsequent proceeding of any kind, except one alleging a breach of this Agreement. 
 9. Violation of Agreement. If
Employee or the Company prevails in a legal or equitable action claiming that the other party has breached this Agreement, the prevailing party shall be entitled to recover from the other party the reasonable attorneys’ fees and costs incurred
by the prevailing party in connection with such action. 
 10. Severability. The provisions of this Agreement shall be
severable and the invalidity of any provision shall not affect the validity of the other provisions; provided, however, that upon a finding by a court of competent jurisdiction that any release or agreement in Section 2, 4, and 5 above is
illegal, void or unenforceable, the parties agree to execute promptly a release, waiver and/or covenant that is legal and enforceable to the extent permitted by law. 

11. Second General Release. In consideration of certain of the payments and benefits provided in Section 2, Employee agrees to
provide a Second General Release of claims covering the period from the execution of this Agreement through the Separation Date, in the form set forth at Exhibit A hereto, to be executed by Employee on the Separation Date. Employee acknowledges and
agrees that Employee’s execution and delivery of such Second General Release is a condition to receiving certain of the payments and benefits set forth in Section 2.  

12. Governing Law and Jurisdiction. This Agreement shall be governed by and construed in accordance with the laws and judicial
decisions of the Commonwealth of Pennsylvania, without regard to its principles of conflicts of laws. 
 13. Confidentiality. Except
(i) in connection with any action to enforce this Agreement, (ii) in connection with any claim for unemployment compensation, or (iii) as may be specifically required by law, Employee will not in any manner disclose or communicate the
existence of this Agreement or any of the terms or provisions hereof to any other person or entity except: (a) Employee’s accountants and/or financial advisors to the extent necessary to prepare tax returns; (b) Employee’s
attorneys; (c) Employee’s spouse (if any); or (d) to a lender in connection with a bona fide loan application; provided, however, that before any such authorized disclosure, Employee agrees to inform each such person or entity to whom
disclosure is to be made that the existence of this Agreement and every term and provision hereof is confidential and obtain such person’s or entity’s agreement to maintain the confidentiality of the existence of this Agreement and the
entire Agreement. Nothing in the foregoing shall prevent Employee from disclosing or discussing with any person any information that has been previously disclosed by the Company in any SEC or other public filings. 

  
 5 

 14. Indemnification. The Indemnification Agreement dated August 2020
(“Indemnification Agreement”) between Employee and Harmony Biosciences Holdings, Inc. (“HBH”) shall remain in full force and effect. Employee’s rights under the Indemnification Agreement shall be in addition to, and not in
lieu of, any other rights to indemnity that Employee has under applicable law, under the organizational documents of the Company, HBH, or any affiliated entity, under any insurance policies maintained by the Company, HBH or any affiliated entity, or
otherwise. 
 15. Revocation Period. Employee has the right to revoke Employee’s release of claims under the Age Discrimination
in Employment Act described in Section 4 above (the “ADEA Release”) for up to seven (7) days after Employee signed and returned it to the Company (the “ADEA Release Revocation Expiry Date”). In order to do so, Employee
must sign and send a written notice of the decision to do so, addressed to the Company’s General Counsel at Harmony Biosciences, LLC, 630 W. Germantown Pike, Suite 215, Plymouth Meeting, PA 19462, and that written notice must be received by the
Company no later than 5:00 p.m. (Eastern Time) on the eighth (8th) day after Employee signed and returned this Agreement to the Company. If (a) Employee revokes the ADEA Release in a timely manner under and in accordance with this
Section 14 or (b) Employee fails to sign and return this Agreement to the Company within the twenty-one (21) day period described in Section 15 below, this Agreement (and the offer
represented hereby) shall be null and void in its entirety, and Employee will not be entitled to any of rights or benefits described in this Agreement (including, but not limited to, those with respect to the receipt of any consideration whatsoever
hereunder). 
 16. Voluntary Execution of Agreement. Employee acknowledges that: 

 

	 	a.	 Employee has carefully read this Agreement and fully understands its meaning and has had all questions
regarding its meaning answered satisfactorily; 

  

	 	b.	 Employee has been given the opportunity to take up to twenty-one
(21) days after receiving this Agreement to decide whether to sign it and if Employee returns the signed Agreement prior to the expiration of such twenty-one (21) day period, Employee acknowledges
that Employee is knowingly and voluntarily waiving any right Employee may have to review the Agreement for a longer period; 

  

	 	c.	 Employee understands that the Company is herein EXPRESSLY advising Employee, in writing, to consult with an
attorney before signing it; 

  

	 	d.	 Employee fully understands the contents of this Agreement, and understands that it is a FULL WAIVER AND RELEASE
OF ALL CLAIMS against the Released Parties; 

  

	 	e.	 This FULL WAIVER AND RELEASE OF ALL CLAIMS is given in return for valuable consideration, as provided under the
terms of this Agreement; 

  
 6 

	 	f.	 Employee is signing this Agreement, knowingly, voluntarily and without any coercion or duress in exchange for
the promises referred to in this Agreement and no other representations have been made to Employee to induce or influence the execution of this Agreement; and 

 

	 	g.	 Everything Employee is receiving for signing this Agreement is described in the Agreement itself, and no other
promises or representations have been made to cause Employee to sign it. 

 17. Entire Agreement. This Agreement
contains the entire agreement and understanding between Employee and the Company concerning the matters described herein, and supersedes all prior agreements, discussions, negotiations, and understandings between the Company and Employee; provided,
however, that the Confidentiality Agreement, the Option Agreement and the Indemnification Agreement are specifically preserved. The terms of this Agreement cannot be changed except in a subsequent document signed by Employee and an authorized
representative of the Company. 
 HARMONY BIOSCIENCES, LLC 
  

	
	

					
	By:	 		 	
	 /s/ John C. Jacobs
	 		 	 /s/ Susan L. Drexler

	John C. Jacobs	 		 	Susan L. Drexler
			
	Date: March 4, 2021	 		 	Date: March 9, 2021

  
 7 

 EXHIBIT A 

SECOND GENERAL RELEASE 

This Second General Release is provided by Susan L. Drexler (“Employee”) in accordance with the terms of the Confidential Separation
Agreement and General Release between Employee and Harmony Biosciences, LLC (the “Company”) dated March 4, 2021 (“Agreement”). 

1. Employee Release of Rights and Agreement Not to Sue. Employee (defined for the purpose of this Section 1 as Employee and
Employee’s agents, representatives, attorneys, assigns, heirs, executors, and administrators) fully and unconditionally releases the Company, its parents (including, without limitation, Harmony Biosciences Holdings, Inc.), subsidiaries,
affiliates, indirect affiliates (including, without limitation, Paragon Management Company, Paragon Biosciences, LLC) and any of its or their respective direct or indirect, past or present, directors, officers, managers, employees, agents, insurers,
attorneys, administrators, officials, members, shareholders, divisions, predecessors, successors, employee benefit plans, and the sponsors, fiduciaries, or administrators of the Company’s employee benefit plans (collectively, the “Released
Parties”) from, and agrees not to bring any action, proceeding or suit against any of the Released Parties regarding, any and all liability, claims, demands, actions, causes of action, suits, grievances, debts, sums of money, agreements,
promises, damages, back and front pay, costs, expenses, attorneys’ fees, and remedies of any type, known or unknown, from the effective date of the Agreement through the date on which Employee executes this Second General Release, arising or
that may have arisen out of or in connection with Employee’s employment with or termination of employment from the Company, including, but not limited to, claims, actions or liability under or with respect to: (a) Title VII of the Civil
Rights Act of 1964, the Civil Rights Act of 1991, the Civil Rights Act of 1866, the Age Discrimination in Employment Act, the Americans with Disabilities Act, the Fair Labor Standards Act, the Family and Medical Leave Act, the Workers’
Adjustment and Retraining Notification, the Employee Retirement Income Security Act of 1974, in each case as such act may be amended; (b) any other federal, state or local statute, act, ordinance, or regulation regarding employment, termination
of employment, discrimination in employment or harassment, (c) federal, state or local common law relating to employment contracts, wrongful discharge, defamation, discrimination in employment or harassment or any other matter, and (d) any
other federal, state or local statute, act, ordinance, regulation, constitution or common law or any violation or alleged violation thereof. Excluded from this release and waiver are any claims that cannot be waived by law. Nothing in this Second
General Release shall be construed to prohibit Employee from initiating or maintaining a charge of discrimination with the Equal Employment Opportunity Commission or any of its state or local governmental agency counterparts, or from otherwise fully
cooperating with and/or participating in any investigation by any such agency. Employee is, however, waiving Employee’s right to any monetary recovery should any such agency pursue any claims on Employee’s behalf. Nothing in the foregoing,
or otherwise in this Second General Release Agreement, shall be a release of (i) any claims to enforce this Agreement; (ii) any claims arising out of events occurring after the execution of this Agreement; (iii) any vested rights or
interests in Company retirement, benefit or equity plans; (iv) any claims for unemployment compensation; (v) any claims for indemnity in the event Employee is named or threatened to be named in any lawsuit or other proceeding arising out
of the services she provided to the Company; or (vi) any claims that, as a matter of law, cannot be released by private agreement. 

  
 8 

 Employee agrees and affirms that Employee has been paid, in full, for all hours worked
for the Company. 
 2. Revocation Period. Employee has the right to revoke Employee’s release of claims under the Age
Discrimination in Employment Act described in Section 1 above (the “ADEA Release”) for up to seven (7) days after Employee signed and returned it to the Company (the “ADEA Release Revocation Expiry Date”). In order to
do so, Employee must sign and send a written notice of the decision to do so, addressed to the Company’s General Counsel at Harmony Biosciences, LLC, 630 W. Germantown Pike, Suite 215, Plymouth Meeting, PA 19462, and that written notice must be
received by the Company no later than 5:00 p.m. (Eastern Time) on the eighth (8th) day after Employee signed and returned this Second General Release to the Company. If (a) Employee revokes the ADEA Release in a timely manner under and in
accordance with this Section 2 or (b) Employee fails to sign and return this Second General Release to the Company in a timely manner, this Second General Release (and the offer represented by the Agreement) shall be null and void in its
entirety, and Employee will not be entitled to any of rights or benefits described in this Agreement (including, but not limited to, those with respect to the receipt of any consideration whatsoever hereunder). 

3. Voluntary Execution of Second General Release. Employee acknowledges that: 

 

	 	a.	 Employee has carefully read this Second General Release and fully understands its meaning and has had all
questions regarding its meaning answered satisfactorily; 

  

	 	b.	 Employee has been given the opportunity to take up to twenty-one
(21) days after receiving this Second General Release to decide whether to sign it and if Employee returns the signed Second General Release prior to the expiration of such twenty-one (21) day
period, Employee acknowledges that Employee is knowingly and voluntarily waiving any right Employee may have to review the Second General Release for a longer period; 

 

	 	c.	 Employee understands that the Company is herein EXPRESSLY advising Employee, in writing, to consult with an
attorney before signing it; 

  

	 	d.	 Employee fully understands the contents of this Second General Release, and understands that it is a FULL
WAIVER AND RELEASE OF ALL CLAIMS against the Released Parties; 

  

	 	e.	 This FULL WAIVER AND RELEASE OF ALL CLAIMS is given in return for valuable consideration, as provided under the
terms of the Agreement; 

  

	 	f.	 Employee is signing this Second General Release, knowingly, voluntarily and without any coercion or duress in
exchange for the promises referred to in the Agreement and no other representations have been made to Employee to induce or influence the execution of this Second General Release; and 

  
 9 

	 	g.	 Everything Employee is receiving for signing this Second General Release is described in the Agreement itself,
and no other promises or representations have been made to cause Employee to sign it. 

 HARMONY BIOSCIENCES, LLC 

 

					
	By:	 		 	
			
	  
	 		 	  

	John C. Jacobs	 		 	Susan L. Drexler
			
	Date: 	 		 	Date: 

  
 10

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00323-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00323-of-00352.parquet"}]]